Review Article | Published:

Cardiovascular risks and benefits of moderate and heavy alcohol consumption

Nature Reviews Cardiology volume 12, pages 576587 (2015) | Download Citation

Abstract

The heart and vascular system are susceptible to the harmful effects of alcohol. Alcohol is an active toxin that undergoes widespread diffusion throughout the body, causing multiple synchronous and synergistic effects. Alcohol consumption decreases myocardial contractility and induces arrhythmias and dilated cardiomyopathy, resulting in progressive cardiovascular dysfunction and structural damage. Alcohol, whether at binge doses or a high cumulative lifetime consumption—both of which should be discouraged—is clearly deleterious for the cardiovascular system, increasing the incidence of total and cardiovascular mortality, coronary and peripheral artery disease, heart failure, stroke, hypertension, dyslipidaemia, and diabetes mellitus. However, epidemiological, case–control studies and meta-analyses have shown a U-type bimodal relationship so that low-to-moderate alcohol consumption (particularly of wine or beer) is associated with a decrease in cardiovascular events and mortality, compared with abstention. Potential confounding influences—alcohol-dose quantification, tobacco use, diet, exercise, lifestyle, cancer risk, accidents, and dependence—can affect the results of studies of both low-dose and high-dose alcohol consumption. Mendelian methodological approaches have led to doubts regarding the beneficial cardiovascular effects of alcohol, and the overall balance of beneficial and detrimental effects should be considered when making individual and population-wide recommendations, as reductions in alcohol consumption should provide overall health benefits.

Key points

  • Alcohol, in binge doses or high cumulative lifetime consumption, is clearly deleterious to most cardiovascular events, and produces progressive cardiovascular dysfunction and structural damage, increasing related morbidity and mortality

  • High-dose alcohol consumption raises total and cardiovascular mortality, and increases development of coronary and peripheral artery disease, arrhythmias, dilated cardiomyopathy, heart failure, stroke, arterial hypertension, dyslipidaemia, and diabetes mellitus

  • Alcoholic dilated cardiomyopathy progressively develops in a dose-dependent manner, starting with diastolic dysfunction and leading to systolic dysfunction and congestive heart failure

  • Genetic, racial, and behavioural susceptibility factors influence the degree of alcohol-induced heart damage, and include gender, as women are more sensitive than men to the harmful cardiac effects

  • The deleterious, toxic effect of high-dose alcohol in relation to cardiovascular disease is recognized, and furthermore, alcohol consumption for the benefit of cardiovascular health is not recommended in nonconsumers

  • Although low-dose alcohol decreases mortality, reducing alcohol consumption has global health benefits, and the beneficial versus detrimental effects of low-dose alcohol should be carefully considered

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    , & Alcohol consumption and non-communicable diseases: epidemiology and policy implications. Addiction 106, 1718–1724 (2011).

  2. 2.

    WHO. Global status report on alcohol and health 2014 ed. (World Health Organization, 2014).

  3. 3.

    et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380, 2224–2260 (2012).

  4. 4.

    et al. Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders. Lancet 373, 2223–2233 (2009).

  5. 5.

    , & Chronic diseases and conditions related to alcohol use. Alcohol Res. 35, 155–173 (2013).

  6. 6.

    , & Alcoholic liver disease: pathogenesis, management, and novel targets for therapy. J. Gastroenterol. Hepatol. 28 (Suppl. 1), 77–84 (2013).

  7. 7.

    , & New advances in molecular mechanisms and emerging therapeutic targets in alcoholic liver diseases. World J. Gastroenterol. 20, 12908–12933 (2014).

  8. 8.

    Alcohol and cardiovascular diseases: a historical overview. Ann. NY Acad. Sci. 957, 7–15 (2002).

  9. 9.

    , , & Alcoholic cardiomyopathy. World J. Cardiol. 6, 771–781 (2014).

  10. 10.

    , , , & Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 342, d671 (2011).

  11. 11.

    , , & Alcohol abuse: critical pathophysiological processes and contribution to disease burden. Physiology (Bethesda) 29, 203–215 (2014).

  12. 12.

    et al. The relationship of average volume of alcohol consumption and patterns of drinking to burden of disease: an overview. Addiction 98, 1209–1228 (2003).

  13. 13.

    , , , & Alcohol and cardiovascular health: the dose makes the poison...or the remedy. Mayo Clin. Proc. 89, 382–393 (2014).

  14. 14.

    , & Alcoholic cardiomyopathy. J. Cardiovasc. Med. (Hagerstown) 11, 884–892 (2010).

  15. 15.

    et al. The effects of alcoholism on skeletal and cardiac muscle. N. Engl. J. Med. 320, 409–415 (1989).

  16. 16.

    & Cardiovascular risk is more related to drinking pattern than to the type of alcohol drinks. Neth. J. Med. 66, 467–473 (2008).

  17. 17.

    , , & Alcohol enhanced permeation in model membranes. Part I. Thermodynamic and kinetic analyses of membrane permeation. Int. J. Pharm. 393, 61–67 (2010).

  18. 18.

    et al. Lipid diffusion in alcoholic environment. J. Phys. Chem. B 118, 9349–9355 (2014).

  19. 19.

    , & Cardiac sensitization: methodology and interpretation in risk assessment. Regul. Toxicol. Pharmacol. 38, 78–90 (2003).

  20. 20.

    et al. Alcohol, signaling, and ECM turnover. Alcohol. Clin. Exp. Res. 34, 4–18 (2010).

  21. 21.

    et al. Effects of alcohol consumption and the metabolic syndrome on 10-year incidence of diabetes: The ATTICA study. Diabetes Metab. 41, 152–159 (2015).

  22. 22.

    & Global metabolic profiling for the study of alcohol-related disorders. Bioanalysis 6, 59–77 (2014).

  23. 23.

    et al. Alcoholism: a systemic proinflammatory condition. World J. Gastroenterol. 20, 14660–14671 (2014).

  24. 24.

    et al. Differential effects of moderate or heavy alcohol consumption on circulating adhesion molecule levels. Thromb. Haemost. 88, 52–55 (2002).

  25. 25.

    et al. Molecular and cellular events in alcohol-induced muscle disease. Alcohol. Clin. Exp. Res. 31, 1953–1962 (2007).

  26. 26.

    & pharmacokinetic and pharmacodynamic drug interactions with ethanol (alcohol). Clin. Pharmacokinet. 53, 1115–1136 (2014).

  27. 27.

    , , , & Effects of beer, wine, and liquor in coronary deaths. JAMA 242, 1973–1974 (1979).

  28. 28.

    et al. Alcohol consumption and risk of stroke: a meta-analysis. JAMA 289, 579–588 (2003).

  29. 29.

    & To drink or not to drink? That is the question. Circulation 116, 1306–1317 (2007).

  30. 30.

    , & Alcohol consumption and its contribution to the burden of coronary heart disease in middle-aged and older New Zealanders: a population-based case-control study. N. Z. Med. J. 117, U793 (2004).

  31. 31.

    et al. Moderate alcohol consumption and risk for angina pectoris or myocardial infarction in U.S. male physicians. Ann. Intern. Med. 126, 372–375 (1997).

  32. 32.

    , & Alcohol consumption and risk for coronary heart disease in men with healthy lifestyles. Arch. Intern. Med. 166, 2145–2150 (2006).

  33. 33.

    Risk factors. Reducing alcohol intake improves heart health. Nat. Rev. Cardiol. 11, 495 (2014).

  34. 34.

    Alcohol and cardiovascular disease. BMJ 349, g4334 (2014).

  35. 35.

    & Moderate ethanol ingestion and cardiovascular protection: from epidemiologic associations to cellular mechanisms. J. Mol. Cell. Cardiol. 52, 93–104 (2012).

  36. 36.

    & Effects of alcohol on skeletal and cardiac muscle. Muscle Nerve 30, 689–707 (2004).

  37. 37.

    et al. Dose dependent but non-linear effects of alcohol on the left and right ventricle. Heart 86, 417–423 (2001).

  38. 38.

    et al. The effect of controlled drinking in alcoholic cardiomyopathy. Ann. Intern. Med. 136, 192–200 (2002).

  39. 39.

    et al. Alcohol consumption, genetic variants in alcohol dehydrogenases, and risk of cardiovascular diseases: a prospective study and meta-analysis. PLoS ONE 7, e32176 (2012).

  40. 40.

    et al. Testing genetic susceptibility loci for alcoholic heart muscle disease. Alcohol. Clin. Exp. Res. 25, 1409–1413 (2001).

  41. 41.

    , & Focus on: ethnicity and the social and health harms from drinking. Alcohol Res. 35, 229–237 (2013).

  42. 42.

    et al. Impact of alcohol duty reductions on cardiovascular mortality among elderly Chinese: a 10-year time series analysis. J. Epidemiol. Community Health 67, 514–518 (2013).

  43. 43.

    et al. Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy. Ann. Intern. Med. 137, 321–326 (2002).

  44. 44.

    , , , & Cardiac pathology in chronic alcoholics: a preliminary study. J. Postgrad. Med. 60, 372–376 (2014).

  45. 45.

    et al. Evidence of apoptosis in alcoholic cardiomyopathy. Hum. Pathol. 37, 1100–1110 (2006).

  46. 46.

    , , & Effects of ethanol on the contractile function of the heart: a review. Alcohol. Clin. Exp. Res. 18, 121–131 (1994).

  47. 47.

    & Mechanisms of myocardial contractile depression by clinical concentration of ethanol. A study in ferret papillary muscles. J. Clin. Invest. 85, 1462–1467 (1990).

  48. 48.

    et al. Alcohol consumption and risk for congestive heart failure in the Framingham Heart Study. Ann. Intern. Med. 136, 181–191 (2002).

  49. 49.

    , & Holiday heart syndrome revisited after 34 years. Arq. Bras. Cardiol. 101, 183–189 (2013).

  50. 50.

    & Alcohol and arrhythmias: a comprehensive review. J. Cardiovasc. Med. (Hagerstown) 11, 221–228 (2010).

  51. 51.

    , & Alcohol consumption and risk of atrial fibrillation: a prospective study and dose-response meta-analysis. J. Am. Coll. Cardiol. 64, 281–289 (2014).

  52. 52.

    et al. Arrhythmias and the “Holiday Heart”: alcohol-associated cardiac rhythm disorders. Am. Heart J. 95, 555–562 (1978).

  53. 53.

    & Alcohol and sudden cardiac death. Br. Heart J. 68, 443–448 (1992).

  54. 54.

    , & Alcohol and heart muscle disease. Addiction Biol. 2, 9–17 (1997).

  55. 55.

    , , & Cardiac effects of acute ethanol ingestion unmasked by autonomic blockade. Circulation 59, 120–125 (1979).

  56. 56.

    , , , & Cardiovascular effects of acetaldehyde accumulation after ethanol ingestion: their modification by beta-adrenergic blockade and alcohol dehydrogenase inhibition. Alcohol. Clin. Exp. Res. 7, 283–288 (1983).

  57. 57.

    & Alcoholic cardiomyopathy: pathophysiologic insights. Cardiovasc. Toxicol. 14, 291–308 (2014).

  58. 58.

    et al. The relation of alcoholic myopathy to cardiomyopathy. Ann. Intern. Med. 120, 529–536 (1994).

  59. 59.

    & Alcohol and the heart. The long-term effects of alcohol on the cardiovascular system. Arch. Intern. Med. 151, 36–42 (1991).

  60. 60.

    , , , & A rodent model of alcoholic heart muscle disease and its evaluation by echocardiography. Alcohol. Clin. Exp. Res. 25, 457–463 (2001).

  61. 61.

    & Prevalence of clinically occult cardiomyopathy in chronic alcoholism. Am. Heart J. 101, 461–464 (1981).

  62. 62.

    et al. Clinical indications for cardiovascular magnetic resonance (CMR): Consensus Panel report. Eur. Heart J. 25, 1940–1965 (2004).

  63. 63.

    , , & Left ventricular filling impairment in asymptomatic chronic alcoholics. Am. J. Cardiol. 66, 1473–1477 (1990).

  64. 64.

    et al. Diastolic function impairment in alcoholics. Alcohol. Clin. Exp. Res. 24, 1830–1835 (2000).

  65. 65.

    et al. Early changes in left ventricular function in chronic asymptomatic alcoholics: relation to the duration of heavy drinking. J. Am. Coll. Cardiol. 35, 1599–1606 (2000).

  66. 66.

    et al. The greater risk of alcoholic cardiomyopathy and myopathy in women compared to men. JAMA 274, 149–154 (1995).

  67. 67.

    et al. Comparison of alcoholic cardiomyopathy in women versus men Am. J. Cardiol. 80, 481–485 (1997).

  68. 68.

    et al. Acute ethanol intake induces superoxide anion generation and mitogen-activated protein kinase phosphorylation in rat aorta: a role for angiotensin type 1 receptor. Toxicol. Appl. Pharmacol. 264, 470–478 (2012).

  69. 69.

    et al. Left atrial function by Speckle-Tracking Echocardiography in chronic asymptomatic alcoholic patients. Cardiovasc. Toxicol. 15, 189–196 (2015).

  70. 70.

    Alcoholic cardiomyopathy: incidence, clinical characteristics, and pathophysiology. Chest 121, 1638–1650 (2002).

  71. 71.

    et al. Alcohol consumption and risk of heart failure: the Atherosclerosis Risk in Communities Study. Eur. Heart J. 36, 939–945 (2015).

  72. 72.

    & Alcohol consumption and heart failure. J. Card. Fail. 11, 329–332 (2005).

  73. 73.

    et al. The association of alcohol consumption and incident heart failure: the Cardiovascular Health Study. J. Am. Coll. Cardiol. 48, 305–311 (2006).

  74. 74.

    , , , & Low-to-moderate alcohol intake and health status in heart failure patients. J. Card. Fail. 11, 323–328 (2005).

  75. 75.

    , , & Moderate alcohol consumption and risk of heart failure among older persons. JAMA 285, 1971–1977 (2001).

  76. 76.

    Reversibility of alcoholic cardiomyopathy. Postgrad. Med. J. 60, 151–154 (1984).

  77. 77.

    & Mechanisms of alcoholic heart disease. Ther. Adv. Cardiovasc. Dis. 2, 497–506 (2008).

  78. 78.

    , & Clinical and histologic features of alcohol drinkers with congestive heart failure. Am. Heart J. 125, 808–817 (1993).

  79. 79.

    , & Ultrastructural and histochemical observations in human and experimental alcoholic cardiomyopathy. J. Am. Coll. Cardiol. 8, 22A–32A (1986).

  80. 80.

    & A histopathological study of dilated cardiomyopathy—with special reference to clinical and pathological comparisons of the degeneration-predominant type and fibrosis-predominant type. Jpn. Circ. J. 51, 654–660 (1987).

  81. 81.

    et al. High-dose alcohol induces reactive oxygen species-mediated apoptosis via PKC-β/p66Shc in mouse primary cardiomyocytes. Biochem. Biophys. Res. Commun. 456, 656–661 (2015).

  82. 82.

    et al. Increased myostatin activity and decreased myocyte proliferation in chronic alcoholic cardiomyopathy. Alcohol. Clin. Exp. Res. 35, 1220–1229 (2011).

  83. 83.

    , , & Insulin-like growth factor 1 myocardial expression decreases in chronic alcohol consumption. Regen. Med. Res. 1, 3 (2013).

  84. 84.

    et al. Harmful and beneficial relationships between alcohol consumption and subclinical atherosclerosis. Nutr. Metab. Cardiovasc. Dis. 24, 767–776 (2014).

  85. 85.

    , & The year in atherothrombosis. J. Am. Coll. Cardiol. 60, 932–942 (2012).

  86. 86.

    , & Alcohol consumption before myocardial infarction. Results from the Kaiser-Permanente epidemiologic study of myocardial infarction. Ann. Intern. Med. 81, 294–301 (1974).

  87. 87.

    , , , & Prevention of cardiovascular risk by moderate alcohol consumption: epidemiologic evidence and plausible mechanisms. Intern. Emerg. Med. 5, 291–297 (2010).

  88. 88.

    Alcohol and cardiovascular mortality: common sense and scientific truth. J. Am. Coll. Cardiol. 55, 1336–1338 (2010).

  89. 89.

    , , , & Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors. BMJ 319, 1523–1528 (1999).

  90. 90.

    , , , & Moderate alcohol use and reduced mortality risk: systematic error in prospective studies. Addiction Res. Theory 14, 101–132 (2006).

  91. 91.

    Demonstration of deductive meta-analysis: ethanol intake and risk of myocardial infarction. Epidemiol. Rev. 15, 328–351 (1993).

  92. 92.

    , , & Review of moderate alcohol consumption and reduced risk of coronary-heart disease: is the effect due to beer, wine, or spirits. BMJ 312, 731–736 (1996).

  93. 93.

    Wine, beer and spirits and the risk of myocardial infarction: a systematic review. Biomed. Pharmacother. 53, 417–423 (1999).

  94. 94.

    , , , & Alcohol and coronary heart disease: a meta-analysis. Addiction 95, 1505–1523 (2000).

  95. 95.

    , , & A meta-analysis of alcohol consumption and the risk of 15 diseases. Prev. Med. 38, 613–619 (2004).

  96. 96.

    , , , & Meta-analysis of wine and beer consumption in relation to vascular risk. Circulation 105, 2836–2844 (2002).

  97. 97.

    et al. Alcohol drinking and cardiovascular risk in a population with high mean alcohol consumption. Am. J. Cardiol. 103, 361–368 (2009).

  98. 98.

    et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 364, 937–952 (2004).

  99. 99.

    et al. Alcohol intake and risk of coronary heart disease in younger, middle-aged, and older adults. Circulation 121, 1589–1597 (2010).

  100. 100.

    , & Alcohol consumption and risk of death in male physicians with heart failure. Am. J. Cardiol. 114, 1065–1068 (2014).

  101. 101.

    , , & Alcohol and mortality: a U-shaped curve. Lancet 317, 580–583 (1981).

  102. 102.

    , , , & Wine, beer or spirit drinking in relation to fatal and non-fatal cardiovascular events: a meta-analysis. Eur. J. Epidemiol. 26, 833–850 (2011).

  103. 103.

    , , & All cause mortality and the case for age specific alcohol consumption guidelines: pooled analyses of up to 10 population based cohorts. BMJ 350, h384 (2015).

  104. 104.

    et al. Moderate alcohol intake, increased levels of high-density lipoprotein and its subfractions, and decreased risk of myocardial infarction. N. Engl. J. Med. 329, 1829–1834 (1993).

  105. 105.

    , , , & Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 342, d636 (2011).

  106. 106.

    & Wine and cardiovacular disease. Nutr. Metab. Cardiovasc. Dis. 11 (Suppl. 4), 47–50 (2001).

  107. 107.

    , & Light-to-moderate alcohol intake is associated with enhanced insulin sensitivity. Diabetes Care 17, 115–119 (1994).

  108. 108.

    Effects of ethanol intake on lipoproteins and atherosclerosis. Curr. Opin. Lipidol. 21, 346–351 (2010).

  109. 109.

    , & Administration of wine and grape juice inhibits in vivo platelet activity and thrombosis in stenosed canine coronary arteries. Circulation 91, 1182–1188 (1995).

  110. 110.

    et al. Effect of low doses of ethanol on platelet function in long-life abstainers and moderate-wine drinkers. Life Sci. 73, 1557–1566 (2003).

  111. 111.

    et al. Mechanism by which alcohol and wine polyphenols affect coronary heart disease risk. Ann. Epidemiol. 17 (Suppl. 5), S24–S31 (2007).

  112. 112.

    et al. Inflammatory markers of atherosclerosis are decreased after moderate consumption of cava (sparkling wine) in men with low cardiovascular risk. J. Nutr. 137, 2279–2284 (2007).

  113. 113.

    & Ethanol does not exert myocardial preconditioning in an intact rabbit model of ischemia/reperfusion. Heart Dis. 3, 293–296 (2001).

  114. 114.

    et al. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 349, g4164 (2014).

  115. 115.

    Alcohol's evaporating health benefits. BMJ 350, h407 (2015).

  116. 116.

    Alcohol consumption and incident cardiovascular disease: not just one unifying hypothesis. Eur. Heart J. 36, 897–898 (2015).

  117. 117.

    , & Alcohol and cardiovascular health: the razor-sharp double-edged sword. J. Am. Coll. Cardiol. 50, 1009–1014 (2007).

  118. 118.

    et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. N. Engl. J. Med. 348, 109–118 (2003).

  119. 119.

    et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N. Engl. J. Med. 368, 1279–1290 (2013).

  120. 120.

    & Alcohol and coronary heart disease: the answer awaits a randomized controlled trial. Circulation 112, 1379–1381 (2005).

  121. 121.

    & The French paradox and wine drinking. Novartis Found. Symp. 216, 208–217 (1998).

  122. 122.

    et al. Type of alcohol consumed and mortality from all causes, coronary heart disease, and cancer. Ann. Intern. Med. 133, 411–419 (2000).

  123. 123.

    , & The relationship between wine consumption and cardiovascular risk; from epidemiological evidence to biological plausability. Ital. Heart J. 2, 1–8 (2001).

  124. 124.

    & Resveratrol: a cardioprotective substance. Ann. NY Acad. Sci. 1215, 16–21 (2011).

  125. 125.

    , , & Effects of wine, alcohol and polyphenols on cardiovascular disease risk factors: evidences from human studies. Alcohol Alcohol. 48, 270–277 (2013).

  126. 126.

    et al. Wine, beer, alcohol and polyphenols on cardiovascular disease and cancer. Nutrients 4, 759–781 (2012).

  127. 127.

    et al. Effects of alcohol and polyphenols from beer on atherosclerotic biomarkers in high cardiovascular risk men: a randomized feeding trial. Nutr. Metab. Cardiovasc. Dis. 25, 36–45 (2015).

  128. 128.

    et al. Alcohol consumption and the risk of morbidity and mortality for different stroke types—a systematic review and meta-analysis. BMC Public Health 10, 258 (2010).

  129. 129.

    et al. Co-morbidities and mortality associated with intracranial bleeds and ischaemic stroke. Int. J. Neurosci. .

  130. 130.

    et al. Alcohol and the risk for ischemic stroke in men: the role of drinking patters and usual beverage. Ann. Intern. Med. 142, 11–19 (2005).

  131. 131.

    , , , & An expanding knowledge of the mechanisms and effects of alcohol consumption on cardiovascular disease. J. Cardiopulm. Rehabil. Prev. 34, 159–171 (2014).

  132. 132.

    et al. Alcohol consumption and risk of stroke among middle-aged men: the JPHC Study Cohort I. Stroke 35, 1124–1129 (2004).

  133. 133.

    & Alcohol drinking and peripheral arterial disease of lower extremity [Japanese]. Nihon Arukoru Yakubutsu Igakkai Zasshi 49, 13–27 (2014).

  134. 134.

    & Neurological and electrophysiological parameters as outcome measurements for peripheral arterial occlusive disease. Ann. Vasc. Surg. 28, 1703–1711 (2014).

  135. 135.

    et al. Relation between alcohol consumption and arterial stiffness: a cross-sectional study of middle-aged Japanese women and men. Alcohol 47, 643–649 (2013).

  136. 136.

    et al. Association of drinking pattern and alcohol beverage type with the prevalence of metabolic syndrome, diabetes, coronary heart disease, stroke, and peripheral arterial disease in a Mediterranean cohort. Angiology 58, 689–697 (2008).

  137. 137.

    , , & Role of endothelial adenosine receptor-mediated vasorelaxation in ethanol-induced hypotension in hypertensive rats. Eur. J. Pharmacol. 452, 205–214 (2002).

  138. 138.

    et al. Cardiovascular alterations at different stages of hypertension development during ethanol consumption: time-course of vascular and autonomic changes. Toxicol. Appl. Pharmacol. 280, 245–255 (2014).

  139. 139.

    & Pressor effect of alcohol in hypertension. Lancet 1, 119–122 (1984).

  140. 140.

    et al. Prospective study of nutritional factors, blood pressure, and hypertension among US women. Hypertension 27, 1065–1072 (1996).

  141. 141.

    , & Alcohol-induced hypertension: Mechanism and prevention. World J. Cardiol. 6, 245–252 (2014).

  142. 142.

    & Alcohol intake and cardiovascular risk factor profile in men participating in the WOBASZ study. Kardiol. Pol. 71, 359–365 (2013).

  143. 143.

    & Alcohol consumption and heart failure in hypertensive US male physicians. Am. J. Cardiol. 102, 593–597 (2008).

  144. 144.

    , & Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J. Clin. Hypertens. (Greenwich) 14, 792–798 (2012).

  145. 145.

    , & Alcohol and the cardiovascular system: a double-edged sword. Curr. Pharm. Des. 20, 6276–6288 (2014).

  146. 146.

    , , , & Contribution of ALDH2 polymorphism to alcoholism-associated hypertension. Recent Pat. Endocr. Metab. Immune Drug Discov. 8, 180–185 (2014).

  147. 147.

    et al. Effect of alcohol abstinence on blood pressure: assessment by 24-hour ambulatory blood pressure monitoring. Hypertension 33, 653–657 (1999).

  148. 148.

    et al. Analysis on associated factors of uncontrolled hypertension among elderly hypertensive patients in Southern China: a community-based, cross-sectional survey. BMC Public Health 14, 903 (2014).

  149. 149.

    et al. Association between alcohol use and cardiovascular self-care behaviors among male hypertensive veterans affairs outpatients: a cross-sectional study. Subst. Abus. 36, 6–12 (2014).

  150. 150.

    , & Alcohol and public health. Lancet 365, 519–530 (2005).

  151. 151.

    & Alcohol for the prevention of type 2 diabetes mellitus? Treat. Endocrinol. 2, 145–152 (2003).

  152. 152.

    et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 102, 500–505 (2000).

  153. 153.

    , & Alcohol and type 2 diabetes. A review. Nutr. Metab. Cardiovasc. Dis. 20, 366–375 (2010).

  154. 154.

    et al. Effect of moderate red wine intake on cardiac prognosis after recent acute myocardial infarction of subjects with Type 2 diabetes mellitus. Diabet. Med. 23, 974–981 (2006).

  155. 155.

    Diabetes mellitus and alcohol. Diabetes Metab. Res. Rev. 20, 263–267 (2004).

  156. 156.

    , , & Alcohol consumption and type 2 diabetes among older adults: the Cardiovascular Health Study. Obesity (Silver Spring) 15, 1758–1765 (2007).

  157. 157.

    et al. Effects of red wine polyphenols and alcohol on glucose metabolism and the lipid profile: a randomized clinical trial. Clin. Nutr. 32, 200–206 (2013).

  158. 158.

    et al. Beyond HDL-cholesterol increase: phospholipid enrichment and shift from HDL3 to HDL2 in alcohol consumers. J. Lipid Res. 48, 1550–1558 (2007).

  159. 159.

    et al. Moderate alcohol use and health: a consensus document. Nutr. Metab. Cardiovasc. Dis. 23, 487–504 (2013).

  160. 160.

    et al. Comparison of apolipoprotein (apoB/apoA-I) and lipoprotein (total cholesterol/HDL) ratio determinants. Focus on obesity, diet and alcohol intake. PLoS ONE 7, e40878 (2012).

  161. 161.

    et al. The association of alcohol and alcohol metabolizing gene variants with diabetes and coronary heart disease risk factors in a white population. PLoS ONE 5, e11735 (2010).

  162. 162.

    , , & C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843 (2000).

  163. 163.

    , & Inflammation and atherosclerosis. Circulation 105, 1135–1143 (2002).

  164. 164.

    et al. Ethanol inhibits activation of NLRP3 and AIM2 inflammasomes in human macrophages—a novel anti-inflammatory action of alcohol. PLoS ONE 8, e78537 (2013).

  165. 165.

    , , & Modulation of inflammation by alcohol exposure. Mediators Inflamm. 2014, 283756 (2014).

  166. 166.

    Moderate alcohol consumption and cancer. Ann. Epidemiol. 17, S46–S48 (2007).

  167. 167.

    , , & Epidemiology and pathophysiology of alcohol and breast cancer: update 2012. Alcohol Alcohol. 47, 204–212 (2012).

  168. 168.

    , , & Managed alcohol as a harm reduction intervention for alcohol addiction in populations at high risk for substance abuse. Cochrane Database of Systematic Reviews, Issue 12. Art. No.: CD006747. .

  169. 169.

    & Alcohol as medication is no good. More risks than benefits according to a survey of current knowledge [Swedish]. Lakartidningen 102, 632–637 (2005).

  170. 170.

    et al. Alcohol attributable burden of incidence of cancer in eight European countries based on results from prospective cohort study. BMJ 342, d1584 (2011).

  171. 171.

    To drink or not to drink? N. Engl. J. Med. 348, 163–164 (2003).

  172. 172.

    et al. Ethanol abolishes ischemic preconditioning in humans. J. Am. Coll. Cardiol. 51, 271–275 (2008).

  173. 173.

    et al. 'Alcohol, less is better' project: outcomes of an Italian community-based prevention programme on reducing per-capita alcohol consumption. Addiction 106, 102–110 (2011).

Download references

Acknowledgements

The author was supported by SGR-2013-1158 Generalitat de Catalunya, and also by the research network CIBEROBN Fisiopatologia de la Obesidad y la Nutrición, Instituto de Salud Carlos III, Madrid, Spain.

Author information

Affiliations

  1. Department of Internal Medicine, Hospital Clínic, University of Barcelona, Villarroel 170, 08036 Barcelona, Spain.

    • Joaquim Fernández-Solà

Authors

  1. Search for Joaquim Fernández-Solà in:

Competing interests

The author declares no competing financial interests.

Corresponding author

Correspondence to Joaquim Fernández-Solà.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nrcardio.2015.91

Further reading